CTNM
CTNM
US21217B1008
Contineum Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
68.059.000 50.894.000
33.7%
Operating Income -68.059.000 -50.894.000
33.7%
Pretax Income -59.978.000 -42.258.000
41.9%
Net Income Common Stockholders -59.978.000 -42.258.000
41.9%
-- --
--
-- --
--
ende